News for China Biologic Products Inc - Google Finance

CHINA BIOLOGIC PRODUCTS INC : China Biologic Products to Report First ...

Thu, 02 May 2013 20:06:40 GMT

CHINA BIOLOGIC PRODUCTS INC : China Biologic Products to Report First ...
4-traders (press release) - May 2, 2013

BEIJING, May 2, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to ...

China Biologic Reports Financial Results for the First Quarter of 2013

Wed, 08 May 2013 21:05:41 GMT

China Biologic Reports Financial Results for the First Quarter of 2013
MSN Money - May 8, 2013

BEIJING, May 8, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the ...

J&J expects 10-plus new drug applications by 2017

Fri, 24 May 2013 05:15:17 GMT

J&J expects 10-plus new drug applications by 2017
Boston Globe - 1 hour ago

Like its rivals, the company says it is focusing on conditions that lack adequate treatments, as well as expanding sales in emerging markets such as China and India. NEW BRUNSWICK, N.J. - Johnson & Johnson is developing what ... J&J, which makes ...

Johnson & Johnson forecasts 10 new drug applications by 2017

Thu, 23 May 2013 18:59:41 GMT

Johnson & Johnson forecasts 10 new drug applications by 2017
Asbury Park Press - 12 hours ago

In this 2011 photo, Johnson & Johnson Band-Aid products are displayed. Johnson & Johnson ... many fatal overdoses.

Oncobiologics forms venture with Chinese company

Wed, 22 May 2013 15:36:33 GMT

Oncobiologics forms venture with Chinese company
NJBIZ - May 22, 2013

Huahai will commercialize four complex biological drugs developed by Oncobiologics for the Chinese market. The products will be manufactured in China at a Huahai facility there. The agreement also establishes a co-development and commercialization ...

Novo A/S acquires Xellia Pharmaceuticals for $ 700 million

Wed, 22 May 2013 18:17:12 GMT

Novo A/S acquires Xellia Pharmaceuticals for $ 700 million
PharmaLive (press release) (subscription) - May 22, 2013

Xellia's life-saving anti-infective products for multi-drug resistant infections address a growing global medical challenge, and the Company is a world leading supplier of Vancomycin and Colistimethate Sodium (CMS). Xellia's products are all ...

Chinese pharma companies look West

Mon, 20 May 2013 00:03:19 GMT

Chinese pharma companies look West
China Daily - May 20, 2013

Chinese biotech company Sino Biological Inc reached an agreement with Life Technologies Corp for protein product distribution and development worldwide. Shanghai Fosun Pharmaceutical (Group) Co has become the largest single shareholder of ...

iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 ...

Wed, 22 May 2013 11:31:32 GMT

iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 ...
PR Newswire (press release) - May 22, 2013

Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene ...

Impax board steps in to oversee Hayward manufacturing issues

Tue, 21 May 2013 01:20:52 GMT

Impax board steps in to oversee Hayward manufacturing issues
San Francisco Business Times (blog) - May 21, 2013

The FDA cited the plant in 2011 for sampling and testing of materials and drug products, product record review and the company's process for inspecting the failure of some manufacturing batches to meet specifications. Those inspections led Impax to ...

Actavis to Buy Warner Chilcott in $5 Billion Deal

Mon, 20 May 2013 11:41:04 GMT

Actavis to Buy Warner Chilcott in $5 Billion Deal
Wall Street Journal - May 20, 2013

Mr. Bisaro said the company would continue to pursue deals to bolster its generics business, specialty pharmaceuticals, as well as biosimilars, which are rough copies of biologic drugs derived from living cells. Actavis, of Parsippany, N.J., said it ...